Parpi - OmicsDI

Show results for

Unknown (934)
Genomics (208)
Transcriptomics (84)
Proteomics (44)
Other (18)
Clinical (2)
Methylation profiling (2)
Metabolomics (2)

Organisms

Homo sapiens (114)
Chlamydomonas reinhardtii (40)
Marchantia polymorpha subsp. ruderalis (40)
Methylocystis sp. (40)
Porites pukoensis (40)
Bothrops insularis (40)
Bothrops jararaca (40)
Bothrops jararacussu (40)
Bothrops cotiara (40)
Streptomyces coelicolor (40)
Burkholderia ubonensis MSMB22 (40)
Pseudomonas aeruginosa PA103 (40)
Artibeus jamaicensis (40)
Morchella importuna (40)
Bothrops brazili (40)
Ixodes scapularis (40)
Bothrops leucurus (40)
Bothrops moojeni (40)
Pseudomonas syringae (40)
Sclerotinia sclerotiorum (40)
Tabanus autumnalis (40)
Brassica napus (40)
Bothrops neuwiedi (40)
Bartonella quintana JK 31 (40)
Bombyx mori (40)
Onchocerca volvulus (40)
Klebsiella pneumoniae (40)
Musca domestica (40)
Brugia malayi (40)
Mus musculus (20)

Organisms

Homo sapiens (111)
Mus musculus (21)
Drosophila melanogaster (1)

Repository

ENA (183)
geo (120)
pride (40)
EGA (6)
biostudies-arrayexpress (3)
iProX (3)
MetaboLights (2)
MassIVE (1)

Tissue

Cell culture (17)
Epithelial cell (12)
Permanent cell line cell (5)
Ovarian surface epithelial cell (3)
Carcinoma cell (1)
Prostate cancer cell (1)
Pancreatic ductal cell (1)
Mammary epithelial cell (1)
Malignant cell (1)
Pancreas (1)
Melanocyte (1)
Egg (1)
Ovary (1)
Macrophage (1)
Cell line cell (1)
Fibroblast (1)
Kidney (1)
Monocyte (1)
Blood (1)

Disease

Malignant neoplasm of ovary (7)
Breast cancer (6)
Cervix carcinoma (3)
Disease free (2)
Neoplasms (1)
Colorectal Neoplasms (1)
Pancreatic carcinoma (1)
Ovary epithelial cancer (1)
Pancreas adenocarcinoma (1)
Prostate adenocarcinoma (1)
Prostate cancer (1)
Pancreatic ductal adenocarcinoma (1)
Chronic myeloid leukemia (1)

Technology Type

Mass Spectrometry (40)
Shotgun proteomics (12)
Bottom-up proteomics (10)
Affinity purification coupled with mass spectrometry proteomics (10)
Top-down proteomics (7)
Data-dependent acquisition (5)
Mass spectrometry assay (2)
Data-independent acquisition (2)
ILLUMINA, Illumina HiSeq 2500 (1)
DiaPASEF (1)
Gel-based experiment (1)

Instrument Platform

Liquid Chromatography MS - positive - hilic (2)
Affymetrix Whole Transcript (1)
Illumina HiSeq 2500 (1)
TimsTOF HT (1)
Liquid Chromatography MS - negative - hilic (1)

Publication Date

2025 (42)
2026 (35)
2024 (24)
2023 (19)
2022 (18)
2019 (13)
2021 (9)
2020 (5)
2018 (2)
2014 (1)

CHEBI ID

CHEBI:14649 (1)
CHEBI:18304 (1)
CHEBI:15927 (1)
CHEBI:15763 (1)
CHEBI:15940 (1)
CHEBI:16960 (1)
CHEBI:15846 (1)
CHEBI:16908 (1)
CHEBI:17154 (1)

Metabolite Name

Nmn (1)
Deamido-NAD (1)
Nicotinamide Riboside (1)
Nicotinate D-ribonucleotide (1)
Adenosine diphosphate ribose (1)
Nicotinic acid (1)
Nadide (1)
Nicotinamide (1)
NADH (1)

First Public Date

2025 (49)
2026 (40)
2023 (24)
2022 (20)
2024 (18)
2019 (13)
2020 (9)
2021 (8)
2018 (1)
2017 (1)

Study status

Withdrawn (1)
Terminated (1)

Study type

Transcription profiling by array (2)
Interventional (2)
DNA-seq (1)

Release Date

2023 (148)
2025 (146)
2022 (145)
2024 (121)
2021 (117)
2020 (80)
2019 (54)
2018 (43)
2026 (23)
2017 (21)
2016 (16)
2014 (14)
2015 (5)
2013 (2)
2012 (2)

Lab affiliation

Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, USA. (4)
Moffitt Cancer Center Tampa, FL, USA (4)
Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, 75390, TX, USA (2)
Proteomics program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark (2)
The Institute of Cancer Research (2)
Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7FZ, UK (1)
Targeting DNA repair in systemic and radiation cancer therapy II.Medical Oncology Dept, Radiotherapy and Radiooncology Dept Research team leader: DSB repair in tumors Mildred Scheel Nachwuchszentrum HaTriCS4 (1)
Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas (1)
Centre de recherche du CHU de Québec - Université Laval (1)
Senior Researcher - Principal Investigator, Computational and Chemical Biology, Istituto Italiano di Tecnologia Via Morego, 30 16163 Genova - Italy Tel: +39 010 28961 - C.F.: 97329350587 - P.Iva: 09198791007 (1)
Spatial Proteomics Lab, Max Delbrück Center for Molecular Medicine Berlin, Germany (1)
Functional Proteomics Institute of Cancer Research (1)
Systems Biology Ireland, University College Dublin. (1)
Department of Laboratory Medicine and Pathology University of Minnesota School of Medicine (1)
Proteomics program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen Current affiliation: Evosep Aps, Denmark (1)
Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), INF280, 69120 Heidelberg, Germany. (1)
Director of The Breast Tumor Immunology Laboratory Women’s Cancer Program Dana-Farber Cancer Institute Instructor in Medicine Harvard Medical School (1)
University at Buffalo (1)
COI-NDM (1)
Proteomics program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark Current affiliation: Evosep Aps, Denmark (1)
Center for Diagnostics, Section Mass Spectrometry and Protemics, University Medical Center Hamburg-Eppednorf, Hamburg, Germany (1)
Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), INF280, 69120 Heidelberg, Germany (1)
Tumor biology, Oncology Research Unit, Pfizer (1)
MOE Key Laboratory of Gene Function and Regulation and Guangzhou Key Laboratory of Healthy Aging Research, School of Life Sciences, Sun Yat-sen University, Guangzhou, 510275, China (1)
Department of Biochemistry and Biophysics, University of Pennsylvania (1)
Department of Molecular Mechanisms of Disease University of Zurich Winterthurerstr. 190 8057 Zurich, Switzerland (1)
University of Pennsylvania, Biochemistry & Biophysics, Philadelphia, PA, 19104, USA (1)
Department of Laboratory Medicine and Pathology, University of Minnesota School of Medicine, Minneapolis, Minnesota 55455, USA (1)
AmsterdamUMC, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, OncoProteomics Laboratory, Amsterdam, The Netherlands (1)
Mass Spectrometry/Proteomics Facility, Netherlands Cancer Institute, Amsterdam, Netherlands (1)

Location

United States (1)

Keyword

PARPi (1)
Rare tumor (1)
CO-338 (1)
Homologous recombination (1)
DNA repair (1)
LODESTAR (1)
Germline (1)
Somatic (1)
PALB2 (1)
RAD51C (1)
RAD51D (1)
BARD1 (1)
BRIP1 (1)
FANCA (1)
RAD51 (1)
RAD51B (1)
HRR (1)
Platinum sensitive (1)
Platinum resistant (1)
Tumor agnostic (1)
Basket trial (1)
Leiomyosarcoma (1)
Ampullary carcinoma (1)
Carcinosarcoma (1)
HRD (1)
PARP inhibitor (1)
Rucaparib (1)
BRCA1 (1)
BRCA2 (1)
Niraparib (1)

Previous page
1 / 130
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 130
Next page

Sort by:

Relevance

Page size

Identification of PARPi sensitive transcripts in prostate cancer

PRJNA484893 | ENA

RNA-Seq of PARPi-resistant ovarian cancer cells

PRJNA988124 | ENA

PARPi resistance screens in BRCA2-deficient cells

PARPi resistance screening in KB2P-3.4 2D cell lines

PRJEB74933 | ENA

Role of ALDH1A1 in PARPi resistance in ovarian cancer

PRJNA938376 | ENA

PARPi after PARPi in epithelial ovarian cancer.

Not available

S-EPMC7840844 | biostudies-literature

PARPi resistance CRISPR screen in WEHI-CS62

Genome-wide PARPi (Rucaparib) resistance CRISPR screen in BRCA1 methylated ovarian cancer cell line WEHI-CS62

PRJEB114638 | ENA

Genomic landscape of BRCA1-deficient tumors upon PARPi treatment

PRJEB25799 | ENA

Genomic landscape of BRCA1-deficient tumors upon PARPi treatment

PRJEB25803 | ENA

Endogenous Nitroalkene Exploits Dependence on Autophagy-Lysosome Pathway in PARPi-Resistant Triple Negative Breast Cancer

PRJNA1265122 | ENA

RNA-Seq of PARPi-resistant ovarian cancer cells

We have previously established an in vitro model of PARPi-resistant ovarian cancer by long-term exposure of UWB1.289 ovarian cancer cells (and their isogenic derivatives UWB1.289+BRCA1) to incrementally ascending olaparib concentrations. After finalizing this model, we performed RNA-seq, in order to...

ORGANISM(S): Homo sapiens

2023-07-31 | GSE235980 | GEO

Previous page
1 / 130
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 130
Next page

Sort by:

Relevance

Page size

1294 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

CHEBI ID

Metabolite Name

First Public Date

Study status

Study type

Release Date

Lab affiliation

Location

Tags

Keyword

OmicsDI is part of the ELIXIR infrastructure

Tweets